Targeting Bcl6 repressed the tumor growth of murine HNSCC which further enhanced the therapeutic efficacy of ICB therapy, indicating that Bcl6 inhibition represents a promising strategy for clinical HNSCC treatment. This evidence concerns the gene BCL6 and head and neck squamous cell carcinoma.